GTPL Hathway Limited (NSE:GTPL)

Revance Therapeutics Revenue

GTPL Hathway had revenue of 9.09B INR in the quarter ending June 30, 2025, with 6.88% growth. This brings the company's revenue in the last twelve months to 35.66B, up 7.53% year-over-year. In the fiscal year ending March 31, 2025, GTPL Hathway had annual revenue of 35.07B with 9.17% growth.

• Revenue (ttm): 35.66B
• Revenue Growth: +7.53%
• P/S Ratio: 0.39
• Revenue / Employee: 50.94M
• Employees: 700
• Market Cap: 13.81B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	35.07B	2.95B	9.17%
Mar 31, 2024	32.12B	5.49B	20.59%
Mar 31, 2023	26.64B	2.30B	9.45%
Mar 31, 2022	24.34B	-648.08M	-2.59%
Mar 31, 2021	24.99B	811.21M	3.36%